The inducible TSD phenotype holds promise for improved therapy prediction based on the presence of TSD+ CSCs, development of novel therapeutic strategies targeting the TSD+ CSC niche or the MYC-HIF-2α stemness pathway, and the use of TSD+ CTCs as a biomarker for treatment response in HNSCC. This evidence concerns the gene EPAS1 and head and neck squamous cell carcinoma.